NeuroVive And Sihuan Pharmaceutical To Develop And Commercialise CicloMulsion® And NeuroSTAT® For Cardio- And Neuroprotection In China
NeuroVive's lead product is CicloMulsion®, the first cyclophilin D inhibitor for the treatment of reperfusion injuries following stenting. CicloMulsion® is currently in a 1000 patient Phase III clinical trial evaluating its ability to reduce reperfusion injuries in patients with myocardial infarction.
NeuroVive is also developing NeuroSTAT®, a cyclophilin D inhibitor, which is expected to enter a Phase IIa clinical trial in patients with severe traumatic brain injury before the end of 2012. Both indications have huge medical need and for which there are currently no approved pharmaceutical treatment options. CicloMulsion® and NeuroSTAT® are special formulations of cyclosporine for use in acute cardiac and brain injury indications.
NeuroVive's pipeline also includes a cyclophilin D inhibitor for stroke and drug candidates that act on mitochondria to address energy regulation disorders.
NeuroVive´s shares are listed on the Swedish trading platform AktieTorget ( http://www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.About Sihuan Pharmaceutical Sihuan Pharmaceutical ( http://www.sihuanpharm.com) is a leading pharmaceutical company and the largest cardio-cerebral vascular (CCV) drug franchise in China's prescription drug market. It has a successful track record in R&D, manufacturing, sales and marketing of drug products in the top five medical therapeutic areas in China: cardio cerebral vascular system, central nervous system, metabolism, oncology and anti-infective. Sihuan has a differentiated sales and marketing model and well-managed network of over 3,000 distributors who promote and sell its products to hospitals and medical institutions throughout China and has market-leading R&D capabilities, focusing on innovative and first-to-market generic drugs. Sihuan Pharmaceutical has been listed on the Main Board of the Hong Kong Stock Exchange since October 2010. Key Contact NeuroVive Pharmaceutical: Mikael Bronnegard Email: email@example.com Phone No: +46(0)70-299-62-64 SOURCE NeuroVive
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV